ArticleScientific reports2025
Defect-rich MOF-303 as a dual acid-base heterogeneous catalyst for the one-pot Biginelli synthesis of dihydropyrimidinones.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Recyclable CaSiOChemistry, an Asian journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bifunctional MOF-303 (Al) exhibits promising catalytic activity for the Biginelli reaction. However, its intrinsic microporosity may hinder reactant and product diffusion and reducing efficiency. Introducing defects is crucial for enhancing its catalytic performance. In this work, defect-rich MOF-303 was prepared by grinding the hydrothermally synthesized MOF-303 into a fine powder. The resulting material was thoroughly characterized and exhibited excellent catalytic performance in the solvent-free synthesis of diverse dihydropyrimidinones under moderate reaction conditions, achieving yields ranging from 86 to 99%. Moreover, the catalyst was successfully recycled over five cycles with minimal activity loss. The structures of the obtained products were confirmed by IR,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.